Nanopharmaceuticals Market, by Carrier Type (Liposomes, Polymer, Nanocrystals, Inorganic, Protein, and Others), by Application (Oncology, Neurology, Anti-inflammatory, Anti-infective, Cardiovascular, and Others), by End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global industry Insights and Forecast till 2026

  • Published On : Feb 2019 |
  • Pages : 170 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Nanopharmaceuticals Market –Novel Approach for Cancer Treatment

Nanopharmaceuticals play a major role in advance healthcare, as it is widely used in drug delivery. Nanopharmaceuticals differ from other macroscopic level of medicines in its shape and composition and offer advantages over the bulk analogues such as precision targeting and patient compliance.

The global nanopharmaceuticals market size was valued at US$ 28,434.3 million in 2017, and is expected to exhibit a CAGR of 22.1 % over the forecast period (2018–2026).

Figure 1. Global Nanopharmaceuticals Market Value (US$ Mn), by Region, 2017

nanopharmaceuticals market fig-1

Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of cancer and neurological diseases is expected to propel growth of the global nanopharmaceuticals market

Nanopharmaceuticals are used in various conditions such as cancer, neurological disorders, and other diseases. Moreover, high prevalence of cancer globally, is expected to drive the market growth. According to World Health Organization (WHO), September 2018 factsheet, around 9.6 million deaths occurred due to cancer, and the disease was second leading cause of death, globally.

Increasing incidences of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease is expected to propel growth of the global nanopharmaceuticals market over the forecast period. According to the World Alzheimer Report 2015, around 46 million people were diagnosed with dementia worldwide in 2015, which was estimated to increase to around 131.5 million by 2050.

However, possible toxicity issues, and lack of regulatory guidelines are expected to hinder the market growth. The P&T Community Journal, Volume 42, December 2017, stated an example of carbon-based nanopharmaceuticals demonstrating toxicity in several in vitro and in vivo studies. The mechanism behind toxicity is assumed oxidative stress and others.

Figure 2. Global Nanopharmaceuticals Market Share (%), by Carrier Type, 2018 and 2026

nanopharmaceuticals market fig-2

Source: Coherent Market Insights Analysis (2018)

Rising prevalence of chronic diseases in North America is expected to drive the North America nanopharmaceuticals market growth

North America holds dominant position in the global nanopharmaceuticals market, owing to increasing research and development activities in application of nanotechnology in pharmaceuticals and rising prevalence of chronic disorders. According to the Centers for Disease Control and Prevention (CDC) factsheet, around 6 in 10 adults are diagnosed with chronic diseases and 4 in 10 adults have two chronic diseases in the U.S. According to the same source, chronic diseases account for around 75% of healthcare spending in the U.S.

Key manufacturers in the region focuses on developing and innovating new drugs for meeting the needs of patients, which is expected to bolster the market growth over the forecast period. For instance, in October 2012, Celgene Corporation, a U.S.-based company, received approval from the U.S. Food and Drug Administration (FDA) for Abraxane (paclitaxel protein-bound particles for injectable suspension), which is used for first-line treatment of advanced non-small cell lung cancer.

Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to treat patients. For instance, in May 2017, NovoNodisk received Food and Drug Administration (FDA) approval for glycopegylated Rebinyn, which is used to control bleeding and bleeding management in patients diagnosed with hemophilia B.

Key Players

Major players operating in the global nanopharmaceuticals market include Abbott, GlaxoSmithKline plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited.

Nanopharmaceuticals are novel medicine with particle size less than 1 micron, which work on the principle of nanotechnology. Nanopharmaceuticals are widely used in drug delivery as a carrier for therapeutic compound or as a therapeutic compound. Nanopharmaceuticals are designed to target particular cells, tissue or a specific organ.

Market Dynamics

Increasing prevalence of cardiovascular diseases, cancer, and infectious diseases are major factors driving nanopharmaceuticals market growth. The World Health Organization, factsheet September 2018, estimated around 10 million cases of tuberculosis and around 1.6 million deaths from the disease in 2017. Moreover, advantages of nanopharmaceuticals over macroscopic level medicines is expected to boost the market growth. Nanopharmaceuticals can pass the blood brain barrier and can access the remote areas of brain as well as low solubility of the compound can be developed for enhancing its characteristics.

Key features of the study:

  • This report provides in-depth analysis of the nanopharmaceuticals market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global nanopharmaceuticals market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Abbott, GlaxoSmithKline and plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
  • The global nanopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the nanopharmaceuticals market

Detailed Segmentation:

  • Global Nanopharmaceuticals Market, By Carrier:
    • Liposomes
    • Polymer
    • Nanocrystals
    • Inorganic
    • Protein
    • Others
  • Global Nanopharmaceuticals Market, By Application:
    • Oncology
    • Neurology
    • Anti-inflammatory
    • Anti-infective
    • Cardiovascular
    • Others
  • Global Nanopharmaceuticals Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Nanopharmaceuticals Market, By Geography:
    • North America
      • By Carrier:
        • Liposomes
        • Polymer
        • Nanocrystals
        • Inorganic
        • Protein
        • Others
      • By Application:
        • Oncology
        • Neurology
        • Anti-inflammatory
        • Anti-infective
        • Cardiovascular
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Carrier:
        • Liposomes
        • Polymer
        • Nanocrystals
        • Inorganic
        • Protein
        • Others
      • By Application:
        • Oncology
        • Neurology
        • Anti-inflammatory
        • Anti-infective
        • Cardiovascular
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Carrier:
        • Liposomes
        • Polymer
        • Nanocrystals
        • Inorganic
        • Protein
        • Others
      • By Application:
        • Oncology
        • Neurology
        • Anti-inflammatory
        • Anti-infective
        • Cardiovascular
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Carrier:
        • Liposomes
        • Polymer
        • Nanocrystals
        • Inorganic
        • Protein
        • Others
      • By Application:
        • Oncology
        • Neurology
        • Anti-inflammatory
        • Anti-infective
        • Cardiovascular
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Carrier:
        • Liposomes
        • Polymer
        • Nanocrystals
        • Inorganic
        • Protein
        • Others
      • By Application:
        • Oncology
        • Neurology
        • Anti-inflammatory
        • Anti-infective
        • Cardiovascular
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Carrier:
        • Liposomes
        • Polymer
        • Nanocrystals
        • Inorganic
        • Protein
        • Others
      • By Application:
        • Oncology
        • Neurology
        • Anti-inflammatory
        • Anti-infective
        • Cardiovascular
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abbott *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline plc.
    • Eli Lilly and Company
    • Astrazeneca plc.
    • Novavax, Inc.
    • Stryker Corporation
    • OSI Pharmaceuticals
    • Kadmon Pharmaceuticals
    • Samyang Biopharm
    • Mitsubishi Tanabe Pharma Corporation
    • Kaken Pharmaceutical
    • Selecta Biosciences
    • Par Pharmaceutical
    • Cerulean Pharma Inc.
    • Navidea Biopharmaceuticals
    • AbbVie Inc.
    • AMAG Pharmaceuticals
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Celgene Corporation
    • Gilead Sciences, Inc.
    • JOHNSON & JOHNSON
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Hoffmann-La Roche AG
    • Sanofi S.A
    • Shire Plc.
    • Teva Pharmaceuticals Industries Limited.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Carrier Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Nanopharmaceuticals Market, By Carrier Type, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Liposomes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Polymer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Nanocrystals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Inorganic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Protein
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Nanopharmaceuticals Market, By Application, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Oncology
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Neurology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Anti-inflammatory
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Anti-infective
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Cardiovascular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Nanopharmaceuticals Market, By Distribution Channel, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospital Pharmacies
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  7. Global Nanopharmaceuticals Market, By Region, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Carrier Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Countryt 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Carrier Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Carrier Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Carrier Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Carrier Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Carrier Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      •  Abbott Laboratories
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc.
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Astrazeneca plc.
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Novavax, Inc.
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Stryker Corporation
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • OSI Pharmaceuticals
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kadmon Pharmaceuticals
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Samyang Biopharm
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mitsubishi Tanabe Pharma Corporation
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kaken Pharmaceutical
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Selecta Biosciences
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Par Pharmaceutical
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cerulean Pharma Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Navidea Biopharmaceuticals
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AMAG Pharmaceuticals
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Celgene Corporation
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gilead Sciences, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • JOHNSON & JOHNSON
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche AG
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Shire Plc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceuticals Industries Limited.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        •  
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 23 market data tables and 26 figures on "Nanopharmaceuticals Market - Global forecast to 2026".

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.